Deleting death and dialysis: conservative care of cardio-vascular risk and kidney function loss in chronic kidney disease (CKD)

R Vanholder, S Van Laecke, G Glorieux, F Verbeke… - Toxins, 2018 - mdpi.com
The uremic syndrome, which is the clinical expression of chronic kidney disease (CKD), is a
complex amalgam of accelerated aging and organ dysfunctions, whereby cardio-vascular …

[HTML][HTML] Cardiovascular calcifications in chronic kidney disease: potential therapeutic implications

J Bover, P Urena-Torres, JL Górriz, MJ Lloret… - Nefrología (English …, 2016 - Elsevier
Cardiovascular (CV) calcification is a highly prevalent condition at all stages of chronic
kidney disease (CKD) and is directly associated with increased CV and global morbidity and …

Epidemiology of low-proteinuric chronic kidney disease in renal clinics

L De Nicola, M Provenzano, P Chiodini, S Borrelli… - PLoS …, 2017 - journals.plos.org
CKD patients with low-grade proteinuria (LP) are common in nephrology clinics. However,
prevalence, characteristics, and the competing risks of ESRD and death as the specific …

Protection effect of exogenous fibroblast growth factor 21 on the kidney injury in vascular calcification rats

YC Shi, WW Lu, YL Hou, K Fu, F Gan… - Chinese medical …, 2018 - mednexus.org
Background: Chronic kidney disease (CKD) is closely related to the cardiovascular events in
vascular calcification (VC). However, little has known about the characteristics of kidney …

Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and …

J Bover, P Ureña-Torres, MJ Lloret… - Expert opinion on …, 2016 - Taylor & Francis
Introduction: Chronic kidney disease-mineral and bone disorders (CKD-MBD), involving a
triad of laboratory and bone abnormalities, and tissue calcifications, are associated with …

[HTML][HTML] Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of …

SJ Zhao, ZX Wang, L Chen, FX Wang… - Annals of Palliative …, 2022 - apm.amegroups.org
Background: Serum intact fibroblast growth factor 23 (FGF23) levels are progressively
increased in relation to the severity of kidney dysfunction. High serum intact FGF23 …

Moderator's view: phosphate binders in chronic kidney disease patients: a clear 'No'at the moment, but stay tuned

C Zoccali, F Mallamaci - Nephrology Dialysis Transplantation, 2016 - academic.oup.com
Particularly because the risk of harm cannot be safely excluded, the use of phosphate
binders in chronic kidney disease (CKD) patients demands caution. Yet, the clinical inertia …

Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD), coinvolgimento cardiovascolare e prognosi

A Bellasi, M Mangano, A Galassi… - GIORNALE ITALIANO DI …, 2017 - air.unimi.it
Le alterazionidelmetabolismo minerale in corso diinsufficienza renale cronica sono di
frequen te riscontro e si associano a prognosi sfavorevole. Nonostante non sia tuttora chiaro …

Peritoneal phosphate clearance: the effect of peritoneal dialysis modality and peritoneal transport status

A Davenport - Advances in Peritoneal Dialysis, 2018 - discovery.ucl.ac.uk
Hyper-and hypophosphatemia are recognized risk factors for all-cause mortality in
peritoneal dialysis (PD) patients. Recent changes have now focused PD solute clearance …

[HTML][HTML] Calcificaciones cardiovasculares en la enfermedad renal crónica: Potenciales implicaciones terapéuticas

J Bover, P Ureña-Torres, JL Górriz, MJ Lloret, I da Silva… - nefrologia, 2016 - Elsevier
La calcificación cardiovascular (CV) es una condición muy prevalente en todos los estadios
de la enfermedad renal crónica (ERC) y se asocia directamente a una mayor …